Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.32 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.32 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.32 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13712818 | 0.91 | TAAR1 (0.39) | TAAR1MEN1LMNATSHRKMT2A | |
| SCHEMBL1180197 | 0.87 | TAAR1 (0.37) | TAAR1MEN1LMNATSHRKMT2A | |
| SCHEMBL4524217 | 0.85 | L3MBTL1 (0.41) | MEN1KMT2ACA14NPC1RAB9A | |
| SCHEMBL1181113 | 0.83 | TAAR1 (0.41) | TAAR1AOC3NPC1RAB9AL3MBTL1 | |
| SCHEMBL13712817 | 0.81 | TAAR1 (0.38) | TAAR1MEN1LMNATSHRKMT2A | |
| SCHEMBL4512033 | 0.75 | TAAR1 (0.43) | TAAR1MEN1LMNATSHRKMT2A | |
| SCHEMBL1801846 | 0.75 | HDAC1 (0.42) | TAAR1AOC3SSTR4NR1H2PLAAT3 | |
| SCHEMBL4524801 | 0.74 | PTPRC (0.38) | TAAR1TSHRL3MBTL1 | |
| SCHEMBL15316186 | 0.74 | SLC6A2 (0.47) | TAAR1MEN1LMNATSHRKMT2A | |
| SCHEMBL25047631 | 0.74 | TAAR1 (0.44) | TAAR1MEN1KMT2AAOC3CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110245293-A1 | PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2-ADRENOCEPTOR AGONIST | ASTRAZENECA AB (SE) | 2011-10-06 | — | — | US | disclosed |
| US-20110245293-A1 | PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2-ADRENOCEPTOR AGONIST | ASTRAZENECA AB (SE) | 2011-10-06 | — | — | US | disclosed |
| US-20110245293-A1 | PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2-ADRENOCEPTOR AGONIST | ASTRAZENECA AB (SE) | 2011-10-06 | — | — | US | disclosed |
| US-20110190309-A1 | PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A Beta2-ADRENOCEPTOR AGONIST | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2011-08-04 | — | — | US | disclosed |
| US-20110190309-A1 | PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A Beta2-ADRENOCEPTOR AGONIST | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2011-08-04 | — | — | US | disclosed |
| US-20110190309-A1 | PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A Beta2-ADRENOCEPTOR AGONIST | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2011-08-04 | — | — | US | disclosed |
| US-20110046191-A1 | COMBINATION OF A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2-ADRENOCEPTOR AGONIST | ARGENTA DISCOVERY LTD. (GB) | 2011-02-24 | — | — | US | disclosed |
| US-20110046191-A1 | COMBINATION OF A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2-ADRENOCEPTOR AGONIST | ARGENTA DISCOVERY LTD. (GB) | 2011-02-24 | — | — | US | disclosed |
| US-20110046191-A1 | COMBINATION OF A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2-ADRENOCEPTOR AGONIST | ARGENTA DISCOVERY LTD. (GB) | 2011-02-24 | — | — | US | disclosed |
| WO-2010019098-A1 | PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2-ADRENOCEPTOR AGONIST | ASTRAZENECA AB (SE) | 2010-02-18 | — | — | WO | disclosed |
| US-20100016388-A1 | Salts of a Selective Beta-2 Andrenoceptor Agonist | ASTRAZENECA AB (SE) | 2010-01-21 | — | — | US | disclosed |
| US-20100016388-A1 | Salts of a Selective Beta-2 Andrenoceptor Agonist | ASTRAZENECA AB (SE) | 2010-01-21 | — | — | US | disclosed |
| WO-2009154555-A1 | PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA2-ADRENOCEPTOR AGONIST | ASTRAZENECA AB (SE) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009139708-A1 | PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A β2-ADRENOCEPTOR AGONIST | ASTRAZENECA AB (SE) | 2009-11-19 | — | — | WO | disclosed |
| WO-2008104790-A1 | SALTS OF A SELECTIVE BETA-2 ANDRENOCEPTOR AGONIST | ASTRAZENECA AB (SE) | 2008-09-04 | — | — | WO | disclosed |
| WO-2008104776-A1 | COMBINATIONS OF BETA-2-ADRENOCEPTOR AGONISTIC BENZOTHIAZOLONE | ASTRAZENECA AB (SE) | 2008-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016388-A1 | Salts of a Selective Beta-2 Andrenoceptor Agonist | ADRB2, ADRA2A, ADRA2B | TAAR1 75/4885MEN1 4004/4885LMNA 4202/4885 |
| US-20110190309-A1 | PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A Beta2-ADRENOCEPTOR AGONIST | ADRB2, ADRB1, ADRA2A | TAAR1 205/4885MEN1 2492/4885LMNA 2317/4885 |
| US-20110245293-A1 | PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2-ADRENOCEPTOR AGONIST | ADRB2, ADRB1, ADRA2A | TAAR1 206/4885MEN1 2642/4885LMNA 2328/4885 |
| US-20110046191-A1 | COMBINATION OF A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2-ADRENOCEPTOR AGONIST | ADRB2, ADRB1, ADRA2A | TAAR1 187/4885MEN1 2825/4885LMNA 1784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.